Compare FRGT & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRGT | XRTX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Mexico | Canada |
| Employees | N/A | N/A |
| Industry | Professional Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.7M |
| IPO Year | 2021 | 2018 |
| Metric | FRGT | XRTX |
|---|---|---|
| Price | $1.16 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 830.1K | 110.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,728,922.00 | N/A |
| Revenue This Year | $371.03 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.60 | $0.37 |
| 52 Week High | $3.49 | $1.41 |
| Indicator | FRGT | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 34.39 |
| Support Level | $1.09 | $0.38 |
| Resistance Level | $1.42 | $0.58 |
| Average True Range (ATR) | 0.23 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 10.71 | 20.09 |
Freight Technologies Inc is a technology company developing solutions to optimize and automate the supply chain process. Along with its subsidiary, Freight App, Inc, the group is focused on making shipping transparent and efficient. Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international over-the-road (OTR) shipping. The company uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.